Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621

Keyphrases

• Adjuvant Radiation Therapy 100%
• High-grade Prostate Cancer 100%
• NRG Oncology 100%
• Docetaxel 100%
• Post-prostatectomy 100%
• Androgen Deprivation 100%
• Gleason Score 50%
• Systemic Therapy 50%
• Androgen Deprivation Therapy 50%
• Prostate-specific Antigen Nadir 50%
• Progression Rate 33%
• Pathologic 33%
• Tumor Classification 33%
• Biochemical Failure 33%
• Post-radical Prostatectomy 33%
• Phase 3 Trial 33%
• High Risk 16%
• Neutropenia 16%
• Prostate-specific Antigen Level 16%
• Clinical High Risk 16%
• Prostate-specific Antigen 16%
• Logistic Regression Analysis 16%
• Multivariate Model 16%
• Radiotherapy 16%
• Cumulative Incidence 16%
• Local Failure 16%
• Radical Prostatectomy 16%
• High-risk Population 16%
• Distant Failure 16%
• Late Toxicity 16%
• Prostatectomy 16%
• Local Therapy 16%
• Febrile Neutropenia 16%
• Risk of Progression 16%
• Expected Rate 16%
• Multivariate Cox Regression Analysis 16%
• Gleason Score 7 16%
• 6-cycles 16%
• Adverse Factors 16%
• 95% Confidence Interval 16%

Medicine and Dentistry

• Prostate Cancer 100%
• Oncology 100%
• Androgen 100%
• Docetaxel 100%
• Radiation Therapy 100%
• Prostate Specific Antigen 71%
• Gleason Score 57%
• Prostatectomy 57%
• Systemic Therapy 42%
• Androgen Deprivation Therapy 42%
• Tumor Classification 28%
• Malignant Neoplasm 14%
• Neutropenia 14%
• Proportional Hazards Model 14%
• Cumulative Incidence 14%
• High Risk Population 14%
• Local Therapy 14%
• Febrile Neutropenia 14%
• Biochemical Recurrence 14%
• Regression Analysis 14%
• Median Follow Up 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Prostate Cancer 100%
• Prostate Specific Antigen 100%
• Androgen 100%
• Docetaxel 100%
• Gleason Score 80%
• Tumor Classification 40%
• Malignant Neoplasm 20%
• Neutropenia 20%
• Febrile Neutropenia 20%
• Biochemical Recurrence 20%